Literature DB >> 20949561

Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study.

Cindy M Chang1, Sophia S Wang, Bhavana J Dave, Smrati Jain, Mohammad A Vasef, Dennis D Weisenburger, Wendy Cozen, Scott Davis, Richard K Severson, Charles F Lynch, Nathaniel Rothman, James R Cerhan, Patricia Hartge, Lindsay M Morton.   

Abstract

The t(14;18) chromosomal translocation is the most common cytogenetic abnormality in non-Hodgkin lymphoma (NHL), occurring in 70-90% of follicular lymphomas (FL) and 30-50% of diffuse large B-cell lymphomas (DLBCL). Previous t(14;18)-NHL studies have not evaluated risk factors for NHL defined by both t(14;18) status and histology. In this population-based case-control study, t(14;18) status was determined in DLBCL cases using fluorescence in situ hybridization on paraffin-embedded tumor sections. Polytomous logistic regression was used to evaluate the association between a wide variety of exposures and t(14;18)-positive (N=109) and -negative DLBCL (N=125) and FL (N=318), adjusting for sex, age, race, and study center. Taller height, more lifetime surgeries, and PCB180 exposure were associated with t(14;18)-positivity. Taller individuals (third tertile vs. first tertile) had elevated risks of t(14;18)-positive DLBCL (odds ratio [OR] = 1.8, 95% confidence interval [CI] 1.1-3.0) and FL (OR=1.4, 95%CI 1.0-1.9) but not t(14;18)-negative DLBCL. Similar patterns were seen for individuals with more lifetime surgeries (13+ vs. 0-12 surgeries; t(14;18)-positive DLBCL OR=1.4, 95%CI 0.7-2.7; FL OR=1.6, 95%CI 1.1-2.5) and individuals exposed to PCB180 greater than 20.8 ng/g (t(14;18)-positive DLBCL OR=1.3, 95%CI 0.6-2.9; FL OR=1.7, 95%CI 1.0-2.8). In contrast, termite treatment and high alpha-chlordane levels were associated with t(14;18)-negative DLBCL only, suggesting that these exposures do not act through t(14;18). Our findings suggest that putative associations between NHL and height, surgeries, and PCB180 may be t(14;18)-mediated and provide support for case-subtyping based on molecular and histologic subtypes. Future efforts should focus on pooling data to confirm and extend previous research on risk factors for t(14;18)-NHL subtypes.
Copyright © 2010 UICC.

Entities:  

Mesh:

Year:  2010        PMID: 20949561      PMCID: PMC3125462          DOI: 10.1002/ijc.25717

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

1.  Meat and meat-mutagen intake and risk of non-Hodgkin lymphoma: results from a NCI-SEER case-control study.

Authors:  Amanda J Cross; Mary H Ward; Maryjean Schenk; Martin Kulldorff; Wendy Cozen; Scott Davis; Joanne S Colt; Patricia Hartge; James R Cerhan; Rashmi Sinha
Journal:  Carcinogenesis       Date:  2005-08-19       Impact factor: 4.944

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma.

Authors:  Brian C-H Chiu; Bhavana J Dave; Aaron Blair; Susan M Gapstur; Shelia Hoar Zahm; Dennis D Weisenburger
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 4.  The non-Hodgkin lymphomas: a review of the epidemiologic literature.

Authors:  Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Ellen T Chang; Philip Cole; Jack S Mandel; Dimitrios Trichopoulos
Journal:  Int J Cancer       Date:  2007       Impact factor: 7.396

5.  Cigarette smoking, familial hematopoietic cancer, hair dye use, and risk of t(14;18)-defined subtypes of non-Hodgkin's lymphoma.

Authors:  Brian C-H Chiu; Bhavana J Dave; Aaron Blair; Susan M Gapstur; Joan S Chmiel; Angela J Fought; Shelia Hoar Zahm; Dennis D Weisenburger
Journal:  Am J Epidemiol       Date:  2007-01-04       Impact factor: 4.897

6.  Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States).

Authors:  Patricia Hartge; Unhee Lim; D Michal Freedman; Joanne S Colt; James R Cerhan; Wendy Cozen; Richard K Severson; Scott Davis
Journal:  Cancer Causes Control       Date:  2006-10       Impact factor: 2.506

7.  Anthropometrics, physical activity, related medical conditions, and the risk of non-hodgkin lymphoma.

Authors:  James R Cerhan; Leslie Bernstein; Richard K Severson; Scott Davis; Joanne S Colt; Aaron Blair; Patricia Hartge
Journal:  Cancer Causes Control       Date:  2005-12       Impact factor: 2.506

Review 8.  Molecular pathways in follicular lymphoma.

Authors:  R J Bende; L A Smit; C J M van Noesel
Journal:  Leukemia       Date:  2006-10-12       Impact factor: 11.528

9.  Dietary determinants of one-carbon metabolism and the risk of non-Hodgkin's lymphoma: NCI-SEER case-control study, 1998-2000.

Authors:  U Lim; M Schenk; L E Kelemen; S Davis; W Cozen; P Hartge; M H Ward; R Stolzenberg-Solomon
Journal:  Am J Epidemiol       Date:  2005-10-12       Impact factor: 4.897

10.  Residential insecticide use and risk of non-Hodgkin's lymphoma.

Authors:  Joanne S Colt; Scott Davis; Richard K Severson; Charles F Lynch; Wendy Cozen; David Camann; Eric A Engels; Aaron Blair; Patricia Hartge
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-02       Impact factor: 4.254

View more
  9 in total

1.  Racial differences in three major NHL subtypes: descriptive epidemiology.

Authors:  Yang Li; Yu Wang; Zhuoyue Wang; Danhui Yi; Shuangge Ma
Journal:  Cancer Epidemiol       Date:  2015-01-02       Impact factor: 2.984

Review 2.  SEER cancer registry biospecimen research: yesterday and tomorrow.

Authors:  Sean F Altekruse; Gabriel E Rosenfeld; Danielle M Carrick; Emilee J Pressman; Sheri D Schully; Leah E Mechanic; Kathleen A Cronin; Brenda Y Hernandez; Charles F Lynch; Wendy Cozen; Muin J Khoury; Lynne T Penberthy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12       Impact factor: 4.254

3.  Circulating t(14;18)-positive cells in healthy individuals: association with age and sex but not with smoking.

Authors:  Carsten Hirt; Kerstin Weitmann; Frank Schüler; Thomas Kiefer; Charles S Rabkin; Wolfgang Hoffmann; Gottfried Dölken
Journal:  Leuk Lymphoma       Date:  2013-05-07

4.  Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma.

Authors:  Catherine Bulka; Loretta J Nastoupil; William McClellan; Alexander Ambinder; Adrienne Phillips; Kevin Ward; A Rana Bayakly; Jeffrey M Switchenko; Lance Waller; Christopher R Flowers
Journal:  Cancer       Date:  2013-07-29       Impact factor: 6.860

Review 5.  Longterm management of Polycystic Ovarian Syndrome (PCOS).

Authors:  Gordon W Bates; Richard S Legro
Journal:  Mol Cell Endocrinol       Date:  2012-12-20       Impact factor: 4.102

6.  A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma.

Authors:  Kimberly A Bertrand; Edward Giovannucci; Shumin M Zhang; Francine Laden; Bernard Rosner; Brenda M Birmann
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-26

7.  Influence of reproductive history and exogenous hormone use on prevalence and frequency of circulating t(14;18)-positive cells in a population-based cross-sectional study.

Authors:  Kerstin Weitmann; Carsten Hirt; Sabine Schwarz; Charles Rabkin; Gottfried Dölken; Wolfgang Hoffmann
Journal:  Cancer Causes Control       Date:  2015-01-30       Impact factor: 2.506

8.  Presence of t(14;18) translocation in healthy individuals varies according to ethnic background in the Brazilian population.

Authors:  D Levy; E R M Bertoldi; J L M Ruiz; J Pereira; S P Bydlowski
Journal:  Braz J Med Biol Res       Date:  2017-06-05       Impact factor: 2.590

9.  PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma.

Authors:  Abdul Shukkur Ebrahim; Mustapha Kandouz; Allison Liddane; Hussam Sabbagh; Yuning Hou; Chunying Li; Ayad Al-Katib
Journal:  Oncotarget       Date:  2016-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.